Knight Therapeutics Q2 revenue beats expectations

Knight Therapeutics

07/08/2025 12:52

Overview

Knight fiscal Q2 revenue rises 12% yr/yr, beating analyst expectations

Company reports net loss of C$12.6 mln, impacted by hyperinflation accounting

Knight completed Paladin acquisition, secured $50 mln credit facility with NBC

Outlook

Knight raises 2025 revenue guidance to C$410 mln-C$420 mln

Adjusted EBITDA expected to be 13% of 2025 revenues

Guidance increase due to strong H1 performance and Sumitomo transaction

Assumptions include no major supply disruptions or new generic competition

Result Drivers

REVENUE GROWTH - Driven by key promoted products and transactions with Paladin and Sumitomo

GROSS MARGIN DECLINE - Impacted by hyperinflation accounting in Argentina and product mix changes

NET LOSS INCREASE - Influenced by hyperinflation, increased operating expenses, and financial asset revaluation losses

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
C$107.36 mln
C$95.70 mln (6 Analysts)
Q2 Net Income
-C$12.62 mln
Q2 Operating Expenses
C$48.50 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Knight Therapeutics Inc is C$7.50, about 16.1% above its August 6 closing price of C$6.29

The stock recently traded at 73 times the next 12-month earnings vs. a P/E of 93 three months ago

Press Release: ID:nGNX8vfLNp

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)